HC Wainwright & Co. Reiterates Buy Rating on Telix Pharmaceuticals Limited (TLX)

Market Context

Telix Pharmaceuticals Limited operates in the Healthcare sector. The stock currently trades at $11.74 with a market capitalization of $3.2B.

Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Telix Pharmaceuticals Limited.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Telix Pharmaceuticals Limited

Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 07, 2026	Citigroup	Buy	N/A
Jul 07, 2026	HC Wainwright & Co.	Buy	N/A
Jul 06, 2026	Wedbush	Outperform	N/A
Apr 13, 2026	Wedbush	Outperform	N/A
Apr 13, 2026	HC Wainwright & Co.	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View TLX Stock Page